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Monoclonal antibodies are essential tools in molecular and cellular immunology research. They have 
essentially replaced the polyclonal antibodies in identifying blood groups and detecting cell markers 
and pathogenic agents. The aim of the present study is to produce monoclonal antibody identifying the 
ABO blood groups using the murine hybridoma technology. An anti-A monoclonal antibody A907 was 
selected and estimated for its use in the manufacture of a reagent anti-A. The selected antibody 
specifically reacts with A1, A2, A1B and A2B erythrocytes. It does not recognize B, O, A3 and Ax 
erythrocytes. The A907 monoclonal antibody can be used in blood grouping in association with a 
reagent recognizing the A weak phenotypes. 
 





Monoclonal antibodies are essential tools in research, 
therapy and diagnostic techniques (Pelegrin et al., 2004; 
Borrebaeck, 2000). Certain markers detected by 
monoclonal antibodies can provide information on 
prognosis in patients with cancer (Laack et al., 2002). 
For example, monoclonal antibodies can help to 
establish the tumor nature. But, their large success is 
especially their use in immuno-hematology. Thus, 
monoclonal reagents replaced polyclonal reagents 
because of their fine specificity, availability in great 
quantities and reduced production cost (Nelson et al., 
2000). Our purpose is to produce anti-A monoclonal 




MATERIALS AND METHODS 
 
Immunization and fusion 
 
A female mouse Balb/c aged of 6 weeks was immunized 
intraperitoneally 3 times with 20 x 106 A human erythrocytes 
suspended in physiological serum. The injections were spaced by  
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15 days. Ten days before the fusion, the P3X63Ag8 murine 
myeloma cells at 0.2 to 0.5 x 106 cells/ml were cultured in 75 cm2 
flask (Costar, United-States) containing RPMI medium 1640 
supplemented with 10% of fetal bovine serum (EuroBio, France) 
and incubated at 37°C in humidified atmosphere with 5% CO2. 
Four days after the last injection, the mouse was sacrificed and 
collected splenocytes were fused with P3X63Ag8 murine myeloma 
cells according to the modified protocol of Galfré et al. as described 
previously (Habti et al., 2003) by using polyethylene glycol 4000 
(BDH laboratories, Britain) at 45% in RPMI medium, pH 7.2 and 
containing 5% of dimethylsulfoxyde (BDH laboratory, Britain). The 
hybrid cells were selected by culture in RPMI medium, containing 
15% fetal bovine serum (FBS), 1.3 g/ml hypoxanthine, 1.7 g/ml 
azaserine, 100 UI/ml penicillin and 100 g/ml streptomycin. Then, 
they were distributed in six 96-well plates (Costar, United-States) at 
15 x 106 splenocytes/plate and incubated at 37°C in humidified 





The identification of the secreting hybridomas was realized in 
microplate with A erythrocytes treated with bromelin. The specificity 
of the antibodies was determined by using panels of O erythrocytes 
presenting majority of blood groups systems antigens (Sanofi 
Diagnostic Pasteur, France) and panels of A1, A2, B and AB 
erythrocytes. The secreting clones were cryopreserved in the liquid 
nitrogen, after their clonings by limiting dilution. 
 




               Table 1. Stability (titer and score) of A907 antibody at +37°C with time. 
 
ER D0 (T/S) D15 (T/S) D30 (T/S) D45 (T/S) D60 (T/S) 
A1, AB 256/70 256/70 256/68 128/60 128/60 
A2 32/38 32/38 32/36 16/31 16/28 
 
               ER, erythrocytes; T/S, titer/score; D, day. 
 
 





















                       ER/N, erythrocytes/number; s, second. 
 
 
Evaluation of an anti-A clone 
 
After several clonings, the production of the anti-A monoclonal 
antibody was carried out in culture supernatant. The precipitation in 
ammonium sulfate and HPLC chromatography analysis were both 
performed in order to deduce the monoclonal antibody’s isotype. 
The elution profile of monoclonal antibody was compared at those 
of the IgG and IgM antibodies of reference products, respectively, 
by anti-D clones (Rh1) P3 x 35 and HM10 (Diagast, France). 
The stability of the clone was verified monthly in continuous culture 
by titration of culture supernatant products for 1 year. The stability 
of the antibody molecule was controlled weekly, by titration of 
culture supernatant stored at +37°C for 2 months and at +4°C for 1 
year. The scores were assigned according to the notation 
recommended by the international code. After 1 year of culture, the 
precloned hybridomas was cloned again to control its stability and 
to determine the percentage of secreting clones. 
The O red cells of 10 panels of anti-erythrocytes antibodies 
identification and a panel constituted of 30 A1, 20 A2, 50 B and 50 
AB erythrocytes were used to study the antibody specificity by 
saline and enzymatic techniques. Further, the A2B, A3B, AxB and Ax 
erythrocytes were used for antibody haemagglutination tests on 
opaline plate, in tube and in microplate. 
A private or rare epitope can exist within the normal population. It 
can also be expressed in individuals with certain pathologies. To 
verify if such was present, the selected antibody reactivity was 
compared to those of the anti-A and anti-AB commercial reagents 
(Sanofi Diagnostics Pasteur and Diagast, France) against 
erythrocytes from 20000 blood donors and 1000 patients with an 
automaton PK7200 (Olympus, Japan). 
 
 
RESULTS AND DISCUSSION 
 
Only one clone (A907) was selected and evaluated. The 
elution profile of the A907 antibody in chromatography is 
similar to IgM antibodies profile. The A907 hybridoma 
clone gave 100% secreting clones. The titer of culture 
supernatant is stable; after 1 year at +4°C, it is 256 with 
a score of 70 with A1 and AB red cells, and it is 32 with a 
score of 38  with  the  A2  red  cells.  On  the other  hand,  
the reactivity of the antibody decreases after 45 days of 
storage at +37°C (Table 1). 
The A907 antibody agglutinates the A1, A2 and AB 
erythrocytes exclusively. The study of the A907 antibody 
reactivity with erythrocytes panels confirms its anti-A 
specificity. The A907 antibody does not recognize the A 
weak groups such as A3 and Ax (Table 2). The 
comparative study among blood donors and patients did 
not show any discordance. 
In this work, a murine monoclonal antibody was 
obtained. In order to characterize the antibody, it is 
necessary to clone the hybridoma several times by 
limiting dilution to assure the clone stability and therefore 
its monoclonality (Nelson et al., 2000). The study of the 
antibody reactivity with different erythrocytes confirmed 
its anti-A specificity. The A907 antibody is stable at +4°C 
for more than one year. Clonal and antibody stability 
would make it possible to produce the A907 antibody 
continually as culture supernatant for one year thereby 
reducing the reagent production cost. However, culture 
supernatant concentration is necessary for obtaining 
good reactivity with A2 erythrocytes, and good titer 
superior to the international standards. 
The A907 antibody does not recognize the weak 
groups as A3 and Ax. However, its use in association with 
another antibody recognizing the A3 and Ax groups will 
provide information on ABO system polymorphisms. It 
can also be helpful in studying of their expression in 
cancer. The specificity of the A907 antibody will be 
determined better by studying its reactivity with 
leukocytes and normal and tumorous tissues (Nakagoe 
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